TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9501783
Drug: intra‐umbilical vein
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra‐umbilical vein injection of saline solution plus oxytocin
Study: 9501783
Drug: intra‐umbilical vein
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra‐umbilical vein injection of saline solution alone
Study: 7698575
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg twice daily for 4 months)
Study: 1671875
Drug: 2-chlorodeoxyadenosine (2-CDA)
Normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-chlorodeoxyadenosine (2-CDA) at doses of 3 to 10.7 mg/m2/d, given as a continuous 5-day infusion
Study: 31699716
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application used by community health agents (CHAs) during home visits to improve child-rearing practices and child health indicators.
Study: 31699716
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application used by CHAs.
Study: 28151802
Drug: Erythropoietin (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (40,000 IU) - 1 dose
Study: 28151802
Drug: Erythropoietin (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (40,000 IU) - 2 doses
Study: 28151802
Drug: Erythropoietin (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (40,000 IU) - 3 doses
Study: 28151802
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no doses of erythropoietin)
Study: 23030579
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention including medication reconciliation, inpatient counseling, simple adherence aids, and telephone follow‐up
Study: 20520621
Drug: Saffron (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (30 mg twice daily for 12 weeks)
Study: 10190759
Drug: Sertraline tablet
Normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline tablet formulation made in China (test tablet)
Study: 10190759
Drug: Sertraline tablet
Normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline tablet formulation made in England (reference tablet)
Study: 8027273
Drug: Ovulation induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation induction using a luteinizing hormone-releasing hormone agonist plus human menopausal gonadotrophin
Study: 2574729
Drug: Dilevalol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 100 mg bid for 2 weeks
Study: 2574729
Drug: Dilevalol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 200 mg bid for 2 weeks
Study: 2574729
Drug: Dilevalol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 400 mg bid for 2 weeks
Study: 2574729
Drug: Dilevalol once-a-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol once-a-day dosing (same total daily dose as prior 2 weeks)
Study: 1937998
Drug: Dilevalol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (all doses)
Study: 7342
Drug: beta‐adrenoceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐adrenoceptor antagonists
Study: 31621256
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received mosapride citrate (5 mg, 3 times a day), bifidobacterium triple viable capsules (420 mg, twice a day), omeprazole (40 mg, twice a day), and antibiotics.
Study: 23817699
Drug: salsalate, 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: salsalate, 3.5 g/d
Study: 18294741
Drug: MF59™-adjuvanted vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59™-adjuvanted vaccine
Study: 16754711
Drug: Prasugrel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (40 mg loading, 7.5 mg maintenance, n = 1)
Study: 16754711
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading, 10 mg maintenance, n = 4)
Study: 16754711
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading, 15 mg maintenance, n = 2)
Study: 16754711
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading, 75 mg maintenance, n = 2)
Study: 16754711
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg daily, n = 2)
Study: 12789875
Drug: Fall-focused pharmaceutical
Normalized name: PHARMACEUTICAL GLAZE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fall-focused pharmaceutical intervention program (FFPIP)
Study: 10641431
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions (difficulty level not specified)
Study: 22732098
Drug: Individually prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually prescribed cognitive behavior therapy text modules with online therapist guidance
Study: 18596312
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg IV every 6 hours
Study: 18596312
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg IV every 6 hours
Study: 8523926
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of desmopressin acetate (DDAVP) at a dosage of 0.3 micrograms/kg, 35 minutes prior to plasmapheresis.
Study: 1838424
Drug: ICI 192,605
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 192,605 (100 mg orally)
Study: 6957991
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Pirenzepine daily
Study: 6957991
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Cimetidine daily
Study: 24852584
Drug: Oral bottled
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bottled water
Study: 24852584
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline (maximum 2 L over 2 hours)
Study: 21342170
Drug: 1% nadifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% nadifloxacin cream
Study: 17097761
Drug: Caralluma extract
Normalized name: CARALLUMA FIMBRIATA EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caralluma extract (1 g per day for 60 days)
Study: 8022537
Drug: Gabapentin as
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin as add-on therapy
Study: 29353388
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Study: 29353388
Drug: Conventional anatomic
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional anatomic landmark palpation guidance injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Study: 29353388
Drug: Conventional anatomic
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional anatomic landmark palpation guidance injection
Study: 26861113
Drug: Drug-Eluting Stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stents (DES) with paclitaxel
Study: 16959672
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CI therapy) for subacute therapy group (3 to 9 months after stroke)
Study: 16959672
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CI therapy) for chronic therapy group (1 year after stroke)
Study: 16959672
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of subacute and chronic therapy groups
Study: 14594455
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing lutein, vitamins A, C and E, zinc, and copper
Study: 10671945
Drug: IGF‐I 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I 50 microg/kg subcutaneously thrice daily during a six day study period
Study: 10671945
Drug: IGF‐I treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I treatment
Study: 1341893
Drug: Bretylium tosylate
Normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bretylium tosylate (5 mg/kg every 6 hours for 48-72 hours)
Study: 3897961
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (CTX) 20 mg/kg, two intravenous injections
Study: 26278063
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin peglispro
Study: 20227541
Drug: Mifepristone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone and misoprostol administration intervals between 0 and 72 hours
Study: 20227541
Drug: Mifepristone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone and misoprostol administration intervals less than 8 hours
Study: 20227541
Drug: Longer administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Longer administration intervals (greater than 8 hours)
Study: 18090070
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.5 mg/kg bolus, followed by 4 microg/kg/min infusion)
Study: 15145973
Drug: Lumiracoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib (400 mg daily)
Study: 11920261
Drug: Conventional first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional first-line chemotherapy (ACVBP)
Study: 11920261
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy regimen (VIMMM with ACVBP for induction and VIM and ACVM in consolidation)
Study: 9825369
Drug: i.v. propafenone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. propafenone, 2 mg/kg bolus, followed by 0.0078 mg/kg/min
Study: 9825369
Drug: p.o. propafenone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. propafenone, 600 mg p.o. in a single dose
Study: 9825369
Drug: p.o. flecainide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. flecainide, 300 mg p.o. in a single dose
Study: 9825369
Drug: i.v. amiodarone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. amiodarone, 5 mg/kg bolus, followed by 1.8 g/24 hours
Study: 2655044
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg/day, 40 mg single dose, 20 mg twice a day)
Study: 22248871
Drug: Valsartan/hydrochlorothiazide (160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/hydrochlorothiazide (160/12.5 mg titrated to 320/25 mg)
Study: 22248871
Drug: Amlodipine/hydrochlorothiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/hydrochlorothiazide (5 mg and 10 mg of amlodipine added at weeks 8 and 12)
Study: 20591625
Drug: Creatine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (0.03 g · kg(‐1) · d(‐1); n = 10, 4 women)
Study: 19998583
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination tablet of lamivudine and stavudine
Study: 19998583
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of lamivudine tablet and stavudine capsule
Study: 15687112
Drug: Low bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low bicarbonate (LB; 27 mmol/l)
Study: 15687112
Drug: Standard bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bicarbonate (SB; 35 mmol/l)
Study: 15687112
Drug: High bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bicarbonate (HB; 39 mmol/l)
Study: 12031750
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg (Group D)
Study: 12031750
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 60 mg (Group K)
Study: 10086794
Drug: GM‐CSF 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF 250 microg/m2 for 3 days followed by G‐CSF 10 microg/kg for 3 days (GM+G)
Study: 10086794
Drug: G‐CSF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 10 microg/kg for 6 days (G‐alone)
Study: 10086794
Drug: Intermediate-dose melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate-dose melphalan (IDM 100 mg/m2)
Study: 6355056
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir cream
Study: 35135
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine administration
Study: 35135
Drug: Intragastric antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric antacid instillation
Study: 21900786
Drug: 4-l polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-l polyethylene glycol (PEG) solution (Klean-prep)
Study: 21900786
Drug: 2-l PEG
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-l PEG solution + ascorbic acid (Moviprep)
Study: 21900786
Drug: sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium phosphate (NaP) solution, Phosphoral
Study: 15008996
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (CEE) 0.625 mg/day
Study: 15008996
Drug: Droloxifene 60
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 60 mg/day
Study: 11426524
Drug: ABLC (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABLC (3-5 mg/kg/day for 10 days)
Study: 11426524
Drug: AmBisome (3-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome (3-5 mg/kg/day for 15 days)
Study: 2692092
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled beclomethasone dipropionate (2000 micrograms day‐1 for two weeks)
Study: 1192701
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium loading (100 mmol)
Study: 1192701
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium loading (100 mmol)
Study: 30734413
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (10% lidocaine, 8 puffs, 80 mg total, 3 minutes before procedure)
Study: 30734413
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (0.8 mL normal saline, 3 minutes before procedure)
Study: 21636546
Drug: Oral iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral iloprost
Study: 16490478
Drug: Baclofen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30 mg/day for 10 consecutive days)
Study: 16490478
Drug: Diazepam (0.5-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.5-0.75 mg/kg/day for 6 consecutive days, tapering the dose by 25% daily from day 7 to day 10)
Study: 11421996
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of BDP (1000 microg)
Study: 11421996
Drug: Inhaled BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled BDP (1000 microg)
Study: 11421996
Drug: Oral BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BDP (4000 microg)
Study: 11421996
Drug: Intranasal BDP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal BDP (1344 microg)
Study: 11421996
Drug: Inhaled BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled BDP with charcoal
Study: 11421996
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intranasal BDP
Study: 11421996
Drug: Inhaled BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled BDP
Study: 27013431
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose + adjuvant (100 μg antigen + AlOH)
Study: 27013431
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose + adjuvant (100 μg antigen + AlOH) administered on Days 0-7-30
Study: 27013431
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (50 μg antigen) with or without aluminum hydroxide (AlOH) adjuvant
Study: 24998111
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg kg(‐1) remifentanil (Group 1, n=25)
Study: 24998111
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg kg(‐1) remifentanil and 1 mg kg(‐1) lidocaine (Group 2, n=25)
Study: 24998111
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg kg(‐1) remifentanil (Group 1)
Study: 24998111
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg kg(‐1) remifentanil and 1 mg kg(‐1) lidocaine (Group 2)
Study: 12559244
Drug: Peripheral repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral repetitive magnetic stimulation (rMS) - 10 sessions, each lasting 20 minutes, with 4000 magnetic stimuli administered in 5s trains at 20Hz at the trigger point.
Study: 12559244
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment - application of a non-functioning ultrasound therapy device to the trigger point.
Study: 8039873
Drug: Preimmunization level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preimmunization level of natural HibCP antibodies
Study: 24151766
Drug: Cinacalcet and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet and low doses of vitamin D analogs
Study: 24151766
Drug: Larger, varying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger, varying doses of vitamin D
Study: 16784346
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to entry (e.g., misspelled brand name)
Study: 15303768
Drug: Radiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy + paclitaxel (30 mg/m2 weekly, median six cycles)
Study: 15303768
Drug: Radiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy + paclitaxel (60 mg/m2 weekly, median six cycles)
Study: 28625627
Drug: Toxicity-Adjusted Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicity-Adjusted Dosing (TAD) of cisplatin + etoposide
Study: 28625627
Drug: Fixed Dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dosing (FD) of cisplatin + etoposide
Study: 26251244
Drug: 70 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 μg/kg desmoteplase
Study: 26251244
Drug: 90 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 μg/kg desmoteplase
Study: 23052033
Drug: ACT-077825 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-077825 (500 mg, 1000 mg)
Study: 23052033
Drug: ACT-077825 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-077825 (500 mg)
Study: 23052033
Drug: ACT-077825 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-077825 (1000 mg)
Study: 22073219
Drug: Eplerenone (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25-50 mg once daily for 8 weeks)
Study: 18926569
Drug: Dispersible artemether-lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible artemether-lumefantrine tablets
Study: 18926569
Drug: Crushed artemether-lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed artemether-lumefantrine tablets
Study: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone (RSG) 8 mg
Study: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone (RSG) 2 mg
Study: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone (RSG) 4 mg
Study: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone (RSG) 2, 4, or 8 mg
Study: 12587890
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg body mass(-1))
Study: 8213103
Drug: EE/NET formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/NET formulation (EE 35 micrograms and norethisterone 0.5 mg on days 1‐7 and days 17‐21, elevated to 1.0 mg during days 8‐16)
Study: 8213103
Drug: EE/LGN formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/LGN formulation (EE 30 micrograms on days 1‐6 and days 12‐21, 40 micrograms on days 7‐11, phased levonorgestrel: 50 micrograms (days 1‐6), 75 micrograms (days 7‐11), and 125 micrograms (days 12‐21)
Study: 3777330
Drug: Gentamicin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (single dose)
Study: 30572916
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of GnRH agonist
Study: 30572916
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of GnRH agonist